Alector Stock Down After Latozinemab Failure, Eyes On Phase 2 Catalyst (ALEC)

Alector Inc. ( ALEC ) stock has had quite a volatile year. We saw great momentum from the company as it progressed with Latozinemab through the pipeline. However, in late October, we saw a less-than-positive data readout, which droppedI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me ...